Polycystic ovary syndrome in women with type 1 diabetes mellitus: about three cases

2015 ◽  
Author(s):  
Amira Djermane ◽  
Samia Ould Kablia
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Ovary Syndrome

Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus

Metabolism ◽  
2016 ◽  
Vol 65 (5) ◽  
pp. 804-811 ◽  
Author(s):  
Agnieszka Łebkowska ◽  
Agnieszka Adamska ◽  
Monika Karczewska-Kupczewska ◽  
Agnieszka Nikołajuk ◽  
Elżbieta Otziomek ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Hormone Concentration ◽  
Ovary Syndrome

scholarly journals High Prevalence of the Polycystic Ovary Syndrome and Hirsutism in Women with Type 1 Diabetes Mellitus1

2000 ◽  
Vol 85 (11) ◽  
pp. 4182-4187 ◽  
Author(s):  
Héctor F. Escobar-Morreale ◽  
Belén Roldán ◽  
Raquel Barrio ◽  
Milagros Alonso ◽  
José Sancho ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Normal Serum ◽  
Ovary Syndrome ◽  
Menstrual Dysfunction ◽  
High Prevalence

The current recommendation for strict metabolic control of type 1 diabetes mellitus requires the administration of supraphysiological doses of insulin, which might result in insulin-mediated stimulation of androgen synthesis, as occurs in insulin-resistant states. At present, the prevalence of hyperandrogenic disorders in women with type 1 diabetes mellitus is unknown. Eighty-five women with type 1 diabetes mellitus were evaluated for symptoms and signs of hyperandrogenism. In 68 of the patients, several serum androgen and hormone concentrations were measured. The polycystic ovary syndrome (PCOS) was defined by the presence of menstrual dysfunction, together with clinical and/or biochemical evidence of hyperandrogenism, and exclusion of other etiologies. Eighteen healthy women, menstruating regularly, served as controls for the androgenic profiles. Thirty-three patients (38.8%) presented hyperandrogenic disorders (16 had PCOS, and 17 had hirsutism without menstrual dysfunction). Type 1 diabetic patients with PCOS presented increased serum total and free testosterone concentrations, and serum androstenedione levels, but had normal serum sex hormone-binding globulin and dehydroepiandrosterone-sulfate levels. Hirsute type 1 diabetic women without menstrual dysfunction presented normal serum androgen levels. There were no significant differences between hyperandrogenic and nonhyperandrogenic type 1 diabetes mellitus women in clinical variables such as the duration of diabetes, age at diagnosis of diabetes, conventional or intensive insulin therapy, mean daily insulin dosage, or metabolic control. In conclusion, women with type 1 diabetes mellitus have a high prevalence of hyperandrogenic disorders, including PCOS and hirsutism.

scholarly journals Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus

2013 ◽  
Vol 4 (3) ◽  
pp. 326-329 ◽  
Author(s):  
Arina Miyoshi ◽  
So Nagai ◽  
Masamitsu Takeda ◽  
Takuma Kondo ◽  
Hiroshi Nomoto ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Japanese Women ◽  
Ovary Syndrome ◽  
Ovarian Morphology

MENSTRUAL DISORDERS AND ANDROGEN-RELATED TRAITS IN YOUNG WOMEN WITH TYPE 1 DIABETES MELLITUS: A CLINICAL STUDY

2020 ◽  
Vol 26 (11) ◽  
pp. 1269-1276
Author(s):  
Stavroula A. Paschou ◽  
Andromachi Vryonidou ◽  
Marina Melissourgou ◽  
Ioanna Kosteria ◽  
Dimitrios G. Goulis ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Young Women ◽  
Polycystic Ovary ◽  
Menstrual Disorders ◽  
Ovary Syndrome ◽  
Pcos Group

Objective: To investigate possible causes of menstrual disorders and androgen-related traits in young women with type 1 diabetes mellitus (T1DM). Methods: Fifty-three women with T1DM (duration 8.0 ± 5.6 years), 41 women with (polycystic ovary syndrome) PCOS, and 51 controls matched for age (19.4 ± 4.3 years vs. 21.2 ± 2.7 years vs. 20.8 ± 3.1 years; P>.05) and body mass index (BMI) (22.2 ± 2.7 kg/m2 vs. 21.9 ± 2.0 kg/m2 vs. 21.4 ± 1.9 kg/m2; P>.05) were prospectively recruited. Results: Two women (3.8%) in the T1DM group had not experienced menarche (at 15.5 and 16.6 years); of the rest, 23.5% had oligomenorrhea, 32.1% hirsutism, and 45.3% had acne. The age at menarche was delayed in the T1DM group compared to controls (12.7 ± 1.3 vs. 12.0 ± 1.0 years; P = .004), while no difference was observed with the polycystic ovary syndrome (PCOS) group (12.4 ± 1.2 years). There were no differences in total testosterone (0.43 ± 0.14 ng/mL vs. 0.39 ± 0.14 ng/mL; P>.05), dehydroepiandrosterone sulfate (DHEA-S) (269 ± 112 μg/dL vs. 238 ± 106 μg/dL; P>.05) or Δ4-androstenedione (2.4 ± 1.3 ng/mL vs. 1.9 ± 0.5 ng/mL; P>.05) concentrations between T1DM and controls. However, patients with T1DM had lower sex hormone binding globulin (SHBG) concentrations than controls (61 ± 17 nmol/L vs. 83 ± 18.1 nmol/L; P = .001), which were even lower in the PCOS group (39.5 ± 12.9 nmol/L; P = .001 compared with T1DM). The free androgen index (FAI) was higher in the PCOS group compared with both other groups (T1DM vs. PCOS vs. controls: 2.53 ± 0.54 vs. 7.88 ± 1.21 vs. 1.6 ± 0.68; P<.001). FAI was higher in patients with T1DM compared to controls as well ( P = .038). There was no difference in DHEA-S concentrations between T1DM and PCOS patients (269 ± 112 μg/dL vs. 297 ± 100 μg/dL; P>.05). Conclusion: Menstrual disorders and androgen-related traits in young women with T1DM may be attributed to an increase in androgen bioavailability due to decreased SHBG concentrations. Abbreviations: Δ4A = Δ4-androstenedione; BMI = body mass index; CI = confidence interval; CV = coefficient of variation; DHEA-S = dehydroepiandrosterone sulfate; FAI = free androgen index; HbA1c = glycated hemoglobin; PCOS = polycystic ovary syndrome; RIA = radioimmunoassay; SHBG = sex hormone binding globulin; T1DM = type 1 diabetes mellitus

Type 1 diabetes mellitus and polycystic ovary syndrome

2021 ◽  
Author(s):  
Héctor F. Escobar-Morreale ◽  
Ane Bayona ◽  
Lía Nattero-Chávez ◽  
Manuel Luque-Ramírez
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Ovary Syndrome

Ovarian functions and polycystic ovary syndrome in women with type 1 diabetes mellitus

2013 ◽  
Author(s):  
Zuleyha Karaca ◽  
Fatih Tanriverdi ◽  
Kursad Unluhizarci ◽  
Fahrettin Kelestimur
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Type 1 Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Ovary Syndrome
Sign in / Sign up

Export Citation Format

Share Document